For non-squamous NSCLC patients with either negative (0%) or low positive (1%–49%) PD-L1, the panel recommends pembrolizumab/carboplatin/pemetrexed, atezolizumab/carboplatin/nab-paclitaxel, ABCP regimens, or platinum-based or non-platinum-based two-drug combination chemotherapy. Here, CD274 is linked to non-small cell lung carcinoma.